Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $30.45 and traded as low as $30.05. Definium Therapeutics shares last traded at $30.16, with a volume of 1,131,741 shares changing hands.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on DFTX. Wells Fargo & Company upped their price objective on shares of Definium Therapeutics from $68.00 to $72.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Definium Therapeutics in a report on Thursday, October 15th. Maxim Group set a $55.00 target price on shares of Definium Therapeutics and gave the company a "buy" rating in a report on Friday, August 14th. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of Definium Therapeutics in a research report on Monday, September 14th. Finally, JPMorgan Chase & Co. started coverage on Definium Therapeutics in a research note on Friday, October 9th. They set an "overweight" rating and a $84.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $66.24.
Check Out Our Latest Stock Analysis on DFTX
Definium Therapeutics Stock Performance
The firm has a fifty day simple moving average of $35.91 and a 200-day simple moving average of $30.45. The company has a quick ratio of 6.95, a current ratio of 15.53 and a debt-to-equity ratio of 0.04. The company has a market cap of $4.05 billion, a PE ratio of -9.70 and a beta of 2.23.
Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.09. On average, research analysts forecast that Definium Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.
Insider Transactions at Definium Therapeutics
In other Definium Therapeutics news, insider Matthew T. Wiley sold 3,097 shares of the stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $113,257.29. Following the completion of the sale, the insider directly owned 359,036 shares of the company's stock, valued at approximately $13,129,946.52. This trade represents a 0.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $1,153,783.50. Following the sale, the chief executive officer directly owned 2,213,090 shares of the company's stock, valued at approximately $80,932,701.30. This represents a 1.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 71,098 shares of company stock worth $2,626,115. 2.40% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP acquired a new position in Definium Therapeutics in the 2nd quarter valued at $138,755,000. Russell Investments Group Ltd. lifted its position in Definium Therapeutics by 116.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 331,702 shares of the company's stock worth $12,647,000 after acquiring an additional 178,225 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in Definium Therapeutics during the 2nd quarter worth $6,992,000. Goldman Sachs Group Inc. lifted its position in Definium Therapeutics by 7.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,935,743 shares of the company's stock worth $73,674,000 after acquiring an additional 134,891 shares during the last quarter. Finally, Moody Aldrich Partners LLC boosted its holdings in Definium Therapeutics by 191.8% during the third quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company's stock valued at $5,666,000 after acquiring an additional 97,845 shares during the period. Institutional investors and hedge funds own 27.91% of the company's stock.
Definium Therapeutics Company Profile
(
Get Free Report)
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Definium Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definium Therapeutics wasn't on the list.
While Definium Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.